Loading provider…
Loading provider…
Medical Oncology Physician in Charleston, SC
NPI: 1437233533Primary Practice Location
MUSC MEDICAL CENTER
25 Courtenay Dr, Charleston, SC
Primary Employer
MUSC Physicians
muschealth.org
HQ Phone
Get MD Albert's Phone NumberMobile
Get MD Albert's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
MO State Medical License
SC State Medical License
SC State Medical License
2021 - 2027
FL State Medical License
2017 - 2023
MO State Medical License
2008 - 2018
TN State Medical License
2001 - 2010
NC State Medical License
1999 - 2003
TX State Medical License
1995 - 2001

American Board of Internal Medicine
Medical Oncology
Duke University Hospital
Fellowship • Hematology and Medical Oncology
1997 - 2000
Washington University/B-JH/SLCH Consortium
Residency • Internal Medicine
1993 - 1996
UT Southwestern Medical Center
utsouthwestern.edu
Medical School
Until 1993
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 38 | 70 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 36 | 66 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 29 | 29 |
Novel targets in esophageal and gastric cancer: beyond antiangiogenesis
Authors: Lee, Wooin, Patel, Jignesh H, Lockhart, A Craig
Journal: Expert Opin Investig Drugs
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Authors: Steven Sorscher
Publication Date: 2011-06-08
Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression.
Authors: Timothy Ley, Matthew Strand
Publication Date: 2018-10-31
Lead Sponsor: Washington University School of Medicine
Collaborators: United States Department of Defense, Rising Tide Foundation
Intervention / Treatment: BIOLOGICAL: Mammaglobin-A DNA Vaccine, PROCEDURE: Optional biopsy
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, DRUG: Irinotecan Hydrochloride, DRUG: Berzosertib, PROCEDURE: Biopsy Specimen